Loading
A phase 2 trial of trastuzumab, cetuximab and fOLFIRI (5-FU, leucovorin, irinotecan) in colorectal cancer, run by Sun Yat-sen University, not yet recruiting.
Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer is a phase 2, interventional study registered as NCT07059338 by Sun Yat-sen University, with a registry enrolment figure of 34 participants, started 2025-07-11 and due to reach its primary completion in 2027-12-30. Interventions recorded: Trastuzumab +Cetuximab β+Irinotecan. Conditions listed: HER2 Positive; Colorectal Cancer (CRC). Primary outcome: 6-month progression-free-survival rates. Colorectal eligibility wording from the registry: "* Histologically or cytologically confirmed adenocarcinoma of the colon or rectum with evidence of distant metastasis". Sites: China. No results are recorded here; the registry entry is the source.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag colorectal-deep-dive.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag colorectal-deep-dive.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag colorectal-deep-dive.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag colorectal-deep-dive.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag colorectal-deep-dive.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag colorectal-deep-dive.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.